Close

UPDATE - UBS Initiates Coverage on Human Genome (HGSI) with a Neutral; See Stock Range-Bound as GSK Hovers

April 12, 2012 11:10 AM EDT
Get Alerts HGSI Hot Sheet
Price: $14.24 --0%

Rating Summary:
    3 Buy, 17 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Human Genome (Nasdaq: HGSI) with a Neutral. PT $8.

Analyst, Matthew Harrison, said, "We believe Benlysta, HGS’ biologic for lupus, can penetrate a minority share (10-15%) of the SLE market and achieve ~$1B in 2020E sales. We remain below consensus (though not Street low) through 2015 as we see a slow ramp continuing and downside risk to the stock. However, we are Neutral as we believe Benlysta is worth ~$7 to GSK without terminal value. Thus, the current stock price is getting to a level where valuation might be too interesting for GlaxoSmithKline (NYSE: GSK) to ignore."

To see more ratings on HGSI, Click Here


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Mergers and Acquisitions, New Coverage, Rumors

Related Entities

UBS